| __timestamp | Corcept Therapeutics Incorporated | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 612613000000 |
| Thursday, January 1, 2015 | 36949000 | 650773000000 |
| Friday, January 1, 2016 | 45240000 | 619061000000 |
| Sunday, January 1, 2017 | 62416000 | 628106000000 |
| Monday, January 1, 2018 | 81289000 | 717599000000 |
| Tuesday, January 1, 2019 | 100359000 | 964737000000 |
| Wednesday, January 1, 2020 | 105326000 | 875663000000 |
| Friday, January 1, 2021 | 122356000 | 886361000000 |
| Saturday, January 1, 2022 | 152848000 | 997309000000 |
| Sunday, January 1, 2023 | 184259000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Data in motion
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated from 2014 to 2023.
Takeda, a global leader, has seen its SG&A expenses grow by approximately 72% over the decade, peaking at over 1 trillion yen in 2023. This reflects its strategic investments in global expansion and innovation.
Corcept, a niche player, has experienced a remarkable 428% increase in SG&A expenses, reaching nearly 185 million dollars in 2023. This growth underscores its commitment to expanding its market presence and enhancing operational capabilities.
Both companies demonstrate distinct strategies in managing their SG&A expenses, highlighting the diverse approaches within the pharmaceutical industry.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights